These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21354172)

  • 1. Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity.
    Alemanni M; Rocchetti M; Re D; Zaza A
    J Mol Cell Cardiol; 2011 May; 50(5):910-8. PubMed ID: 21354172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride].
    Rocchetti M; Besana A; Mostacciuolo G; Micheletti R; Ferrari P; Sarkozi S; Szegedi C; Jona I; Zaza A
    J Pharmacol Exp Ther; 2005 Apr; 313(1):207-15. PubMed ID: 15576469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms.
    Rocchetti M; Besana A; Mostacciuolo G; Ferrari P; Micheletti R; Zaza A
    J Pharmacol Exp Ther; 2003 May; 305(2):765-71. PubMed ID: 12606646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
    Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
    J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).
    Micheletti R; Mattera GG; Rocchetti M; Schiavone A; Loi MF; Zaza A; Gagnol RJ; De Munari S; Melloni P; Carminati P; Bianchi G; Ferrari P
    J Pharmacol Exp Ther; 2002 Nov; 303(2):592-600. PubMed ID: 12388640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
    Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
    Torre E; Arici M; Lodrini AM; Ferrandi M; Barassi P; Hsu SC; Chang GJ; Boz E; Sala E; Vagni S; Altomare C; Mostacciuolo G; Bussadori C; Ferrari P; Bianchi G; Rocchetti M
    Cardiovasc Res; 2022 Mar; 118(4):1020-1032. PubMed ID: 33792692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular Mechanisms Underlying the Low Cardiotoxicity of Istaroxime.
    Racioppi MF; Burgos JI; Morell M; Gonano LA; Vila Petroff M
    J Am Heart Assoc; 2021 Jul; 10(14):e018833. PubMed ID: 34219467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
    Ferrandi M; Barassi P; Tadini-Buoninsegni F; Bartolommei G; Molinari I; Tripodi MG; Reina C; Moncelli MR; Bianchi G; Ferrari P
    Br J Pharmacol; 2013 Aug; 169(8):1849-61. PubMed ID: 23763364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cardiac glycosides on excitation-contraction coupling in frog skeletal muscle fibres.
    Sárközi S; Szentesi P; Jona I; Csernoch L
    J Physiol; 1996 Sep; 495 ( Pt 3)(Pt 3):611-26. PubMed ID: 8887770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship.
    Gobbini M; Armaroli S; Banfi L; Benicchio A; Carzana G; Fedrizzi G; Ferrari P; Giacalone G; Giubileo M; Marazzi G; Micheletti R; Moro B; Pozzi M; Scotti PE; Torri M; Cerri A
    J Med Chem; 2008 Aug; 51(15):4601-8. PubMed ID: 18637667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased sarcoplasmic reticulum calcium leak but unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac myocytes.
    Kohlhaas M; Zhang T; Seidler T; Zibrova D; Dybkova N; Steen A; Wagner S; Chen L; Brown JH; Bers DM; Maier LS
    Circ Res; 2006 Feb; 98(2):235-44. PubMed ID: 16373600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ouabain increases sarcoplasmic reticulum calcium release in cardiac myocytes.
    Nishio M; Ruch SW; Kelly JE; Aistrup GL; Sheehan K; Wasserstrom JA
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1181-90. PubMed ID: 14634043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
    Wehrens XH
    Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Istaroxime: a new luso-inotropic agent for heart failure.
    Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
    Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibition of na/ca exchange results in increased cellular Ca2+ load attributable to the predominance of forward mode block.
    Ozdemir S; Bito V; Holemans P; Vinet L; Mercadier JJ; Varro A; Sipido KR
    Circ Res; 2008 Jun; 102(11):1398-405. PubMed ID: 18451338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
    Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
    Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
    Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional coupling between sarcoplasmic reticulum and Na/Ca exchange in single myocytes of guinea-pig and rat heart.
    Janiak R; Lewartowski B; Langer GA
    J Mol Cell Cardiol; 1996 Feb; 28(2):253-64. PubMed ID: 8729058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.